Labeling changes for Viramune.
D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics; D002648:Child; D002675:Child, Preschool; D004348:Drug Labeling; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D019829:Nevirapine / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics; D010372:Pediatrics / Q000592:standards; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics; D014481:United States; D014486:United States Food and Drug Administration
D019380:Anti-HIV Agents; D018894:Reverse Transcriptase Inhibitors; D019829:Nevirapine